Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase II CITYSCAPE study (NCT03563716) of the anti-TIGIT antibody tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
CITYSCAPE: tiragolumab in NSCLC
Теги
Speaker: Melissa JohnsonInstitution: Sarah Cannon Research InstituteEvent: VJVirtualEvent: ASCO 2020Format: InterviewSubject: Non-Small Cell Lung CancerField: TreatmentField: Trial UpdatesTrial: CITYSCAPENCT03563716Medicines: Tiragolumabanti-TIGIT antibodyPD-L1FIeld: Immuno-OncologySubject: Lung Cancer
